论文部分内容阅读
目的:检测MicroRNA-29b(miR-29b)在卵巢上皮性癌组织的表达,并分析miR-29b与卵巢上皮性癌临床病理特征之间的关系。方法:采用实时荧光定量聚合酶链反应(qRT-PCR)定量分析60例卵巢上皮性癌,15例卵巢良性肿瘤及15例正常卵巢组织中miR-29b的表达,并将检测结果与临床指标进行统计学分析。结果:(1)卵巢上皮性癌组织中miR-29b的表达量显著低于正常卵巢及卵巢良性肿瘤组织(P<0.05)。(2)miR-29b表达量与FIGO分期、淋巴结转移及腹水产生相关(P<0.05),与患者年龄、细胞分化、病理类型、残灶直径等临床病理参数无关(P>0.05)。Ⅲ～Ⅳ期和淋巴结转移组的表达量分别低于Ⅰ～Ⅱ期和无淋巴结转移组(P<0.05);腹水组miR-29b的表达量亦低于无腹水组(P<0.05)。(3)Kaplan-Meier法比较生存曲线表明,miR-29b表达量低者术后生存时间短(P<0.05);COX多因素生存分析表明,miR-29b低表达与患者生存时间短独立相关,低表达组的死亡危险度是高表达组的3.996倍。结论:miR-29b可能作为抑癌因子参与了卵巢上皮性癌的发生发展,对卵巢上皮性癌具有潜在的辅助诊断及预后评估意义。
Objective: To detect the expression of MicroRNA-29b (miR-29b) in epithelial ovarian cancer and to analyze the relationship between miR-29b and clinicopathological features of epithelial ovarian cancer. Methods: Quantitative analysis of miR-29b expression in 60 cases of ovarian epithelial carcinoma, 15 cases of benign ovarian tumor and 15 cases of normal ovarian tissue by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR), and the detection results and clinical indicators Statistical analysis. Results: (1) The expression of miR-29b in ovarian epithelial carcinoma was significantly lower than that in normal ovarian and benign ovarian tumors (P <0.05). (2) The expression level of miR-29b was correlated with FIGO stage, lymph node metastasis and ascites production (P <0.05), but not with clinical pathological parameters such as age, cell differentiation, pathological type and residual lesion diameter. The expression of miR-29b in stage Ⅲ-Ⅳ and lymph node metastasis was lower than that in stage Ⅰ-Ⅱ and without lymph node metastasis (P <0.05). The expression of miR-29b in ascites was also lower than that in group without ascites (P <0.05). (3) Kaplan-Meier survival curves showed that the low survival time of patients with low expression of miR-29b (P <0.05); COX multivariate survival analysis showed that the low expression of miR-29b was independently associated with short survival time, The risk of death in the low expression group was 3.996 times higher than in the high expression group. Conclusion: miR-29b may be involved in the development of ovarian epithelial carcinoma as a tumor suppressor factor, and may be a potential adjuvant diagnosis and prognostic evaluation for epithelial ovarian cancer.